Jul 23,2021

Voluntis announces the execution of a Share Purchase Agreement between its reference shareholders and Aptar regarding the acquisition of a majority stake in Voluntis at a price of €8.70 per share

Voluntis, a leader in digital therapeutics, and its reference shareholders (Bpifrance Participations, LBO France Gestion, Debiopharm Innovation Fund, SHAM Innovation Santé, Vesalius Biocapital and Indigo) announced today that following the entry into exclusive negotiations with AptarGroup, Inc. (NYSE: ATR) (“Aptar”) on June 21, 2021, and after completion of the consultation procedure of the employee representative bodies of Voluntis, they have signed a share purchase agreement for the acquisition by Aptar of a majority stake in Voluntis, representing approximately 64.6% of the share capital of Voluntis (on a non-diluted basis), at a price of €8.70 per share.

View Analyst & Ambassador Comments
Go to original news
Jul 26,2021

Senseonics Holdings, Inc. Schedules Second Quarter 2021 Earnings Release and Conference Call for August 9, 2021, at 4:30 p.m. Eastern Time

Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2021 financial results after market close on Monday, August 9, 2021.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jul 26,2021

Insulet to Present at Upcoming Investor Conferences

Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at two upcoming virtual investor conferences: i)The Canaccord 41st Annual Growth Conference on Wednesday, August 11, 2021 at 11:00 a.m. (Eastern Time) ii) The UBS Genomics 2.0 and MedTech Innovations Summit on Thursday, August 12, 2021 at 4:00 p.m. (Eastern Time)

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jul 27,2021

DarioHealth Launches Behavioral Health Solutions Globally in New Partnership with Workplace Options

DarioHealth Corp., a pioneer in the global digital therapeutics market, today announced the launch of its digital behavioral health solution that now includes Workplace Options (WPO) services for its global users. WPO is the largest independent provider of integrated employee wellbeing solutions around the world.

View Analyst & Ambassador Comments
Go to original news
Jul 27,2021

Brighter enters into commercial collaboration agreement with VivBon AB in Sweden for the Actiste® portfolio

Brighter AB announced today that the company has entered into a commercial collaboration agreement with VivBon AB,a Swedish service provider that offers a wide range of personalized services and solutions for seniors and their relatives, to sell Brighter’s Actiste® and Actiste® Mini portfolio for diabetes management. Under this collaboration agreement, Vivbon will actively offer and sell Actiste® and Actiste® Mini to its customers.

COLLABORATION PARTNERSHIP

#institution

#insulin pen

#bgm

View Analyst & Ambassador Comments
Go to original news
Jul 27,2021

BD Board Declares Dividend

The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.83 per common share, payable on September 30, 2021 to holders of record on September 9, 2021. The indicated annual dividend rate is $3.32 per share.

View Analyst & Ambassador Comments
Go to original news
Jul 28,2021

LifeScan Signs Multi-Year Partnership with Noom to Provide Behavior Change Support and Tools

LifeScan, the maker of OneTouch brand products, and Noom, a leading digital health platform focused on behavior change, announced a newly expanded partnership that will empower people with diabetes to take control of their health with Noom’s Diabetes Support Program, which includes psychology-based articles and education, tools including tracking for blood glucose levels, and specialized coaching to help users improve weight management and blood sugar control through behavior change. LifeScan will be the first digital health diabetes management company to partner with Noom to provide Noom’s Diabetes Support Program to consumers

COLLABORATION PARTNERSHIP

#product & service

#bgm

#coaching

View Analyst & Ambassador Comments
Go to original news
Jul 28,2021

Withings and One Drop Partner to Bring Best-In-Class Medical Devices to Multi-Condition Employer Program

Withings, early pioneers of the connected health revolution, and One Drop, a leader in precision health solutions for people living with diabetes and other chronic conditions, are partnering to connect One Drop’s predictive health platform with Withings’ best-in-class smart medical devices for blood pressure and weight management. Together, the companies will bring connected health solutions to employers, empowering workforces worldwide to make more informed decisions and live healthier lives.

COLLABORATION PARTNERSHIP

#connected device

View Analyst & Ambassador Comments
Go to original news
Jul 29,2021

Tandem Diabetes Care Announces Upcoming Conference Presentation

The Company update presentation will be webcast live, and an archive recording will be available for 30 days. The link to the live webcast and archive will be accessible on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jul 29,2021

Effect of Digital-Tool-Supported Basal Insulin Titration Algorithm in Reaching Glycemic Control in Patients with Type 2 Diabetes in Mexico

My Dose Coach (MDC) is a mobile application combined with a web portal that can suggest optimized basal insulin (BI) injection doses using Self-Measured Plasma Glucose (SMPG) and hypoglycemia data. This study aimed to evaluate its efficacy on patients reaching SMPG and Fasting blood glucose (FBG) target range 90-130 mg/dl (5-7.2 mmol/L) goals without severe hypoglycemic episodes. We also addressed the mean reduction in glycated hemoglobin (A1C), FBG, and SMPG and the improvement in the WHO’s Five Well Being Index (WBI).

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES